Beta Bionics, Inc. (BBNX) stock
BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/3013% below fair value
$13.32−1.01 (-7.05%)
Close on Nov 19, 2026Market cap $724.17MP/E –Yield –
Beta Bionics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Beta Bionics's free cash flow for the twelve months ending Sep 30, 2026 was -$65.96M. For fiscal 2025 it was -$56.22M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$56.22M | – |
| FY2024 | Dec 31, 2024 | -$51.67M | – |
| FY2023 | Dec 31, 2023 | -$32.85M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$14.56M | – |
| Q2 FY2026 | Jun 30, 2026 | -$15.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.84M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.55M | – |
See a number that looks wrong?